https://www.avient.com/news/archives?page=2
February 4, 2025
May 14, 2025
May 14, 2025
https://www.avient.com/investors/events-presentations?page=1
Avient Investor Day - December 4, 2024
2025 Earnings Presentations
Avient Q1 2025 Earnings - May 6, 2025
https://www.avient.com/investors/events-presentations?page=11
Avient Investor Day - December 4, 2024
2025 Earnings Presentations
Avient Q1 2025 Earnings - May 6, 2025
https://www.avient.com/investors/events-presentations?page=10
Avient Investor Day - December 4, 2024
2025 Earnings Presentations
Avient Q1 2025 Earnings - May 6, 2025
https://www.avient.com/investors/events-presentations?page=8
Avient Investor Day - December 4, 2024
2025 Earnings Presentations
Avient Q1 2025 Earnings - May 6, 2025
https://www.avient.com/investors/events-presentations?page=3
Avient Investor Day - December 4, 2024
2025 Earnings Presentations
Avient Q1 2025 Earnings - May 6, 2025
https://www.avient.com/sites/default/files/2022-12/Mevopur Colors for Ophthalmic Closures Application Bulletin_A4.pdf
FDA/EU compliance information available upon request
Mevopur™ Healthcare Colorants and Formulations
for Ophthalmic Closures
The Mevopur™ range of standard concentrates
for closures used with ocular (ophthalmic)
medicines matches the color standards from the
American Academy of Ophthalmology (AAO).
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified
manufacturing sites, providing global
consistency and increased security of supply
• Documented change control beyond CAS
number, reducing risk of change
• Non-phthalate and formulated without animal-
derived substances
• Standard concentrates in a PE carrier and
on request in PP
• Pre-colored formulations can be supplied in
specific resins selected for the application
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1 and USP biological
evaluation
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
• Registered Drug Master File (Type III)
• Food contact established with FDA/EU*
APPLICATION BULLETIN
DRUG TYPE COLOR
DESCRIPTION
PANTONE
REFERENCE
AVIENT PRODUCT
CODE PE BASED
Adrenergic agonist
combinations Light Green 373 C PE6M176349
Adrenergic agonists Purple 2583 C PE4M176057
Anti-infectives Tan 467 C PE8M176130
Anti-inflammatory,
nonsteroidal Grey Cool Grey 4 C PE7M176184
steroids Pink 197 C PE3M176237
Anti-inflammatory,
immunomodulators Olive Green 5763 C On request
Beta-blockers Yellow Yellow C PE1M176160
Beta-blocker combinations Dark Blue 281 C PE5M176272
Carbonic anhydrase inhibitors Orange 1585 C PE2M176089
Cytotoxic Black 6 C PL9M176008
Miotics Dark Green 348 C PE6M176267
Mydriatics and cycloplegics Red 1797 C PE3M176236
Prostaglandin analogues Turquoise 326 C PE5M176273
Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2020-09/sustainabilityreport2018.pdf
Pune, India 4.
Edison, New Jersey 4.
Pune, India 4.
https://www.avient.com/investor-center/investor-news/archives
May 14, 2025
May 6, 2025
Fourth quarter sales increased 4% to $747 million and full year sales increased 3% to $3,240 million
Organic sales, which excludes the im
https://www.avient.com/investor-center/investor-news/archives?page=0
May 14, 2025
May 6, 2025
Fourth quarter sales increased 4% to $747 million and full year sales increased 3% to $3,240 million
Organic sales, which excludes the im
